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ABSTRACT 
Objective: The present study was carried out to discover whether these pyrimidine derivatives have the potential to be used as epidermal growth 
factor receptor (EGFR) and carbonic anhydrase (CA) IX inhibitors through structure-based in silico study. 
Methods: Docking was performed on 6 pyrimidine analogs; cetuximab and curcumin were taken as reference drug. The structure of the target 
protein retrieved from the RCSB Protein databank and the protein-ligand docking was performed using Pyrx AutoDock wizard with MGL tools 1.5.6 
by using Lamarckian algorithm.  
Results: All the compounds have shown lower binding energy and inhibition constant (Ki) value than reference drug cetuximab and curcumin. Out 
of the 6 inhibitors analyzed vkh has shown minimum binding energy against the target protein EGFR and CA IX respectively. Smaller Ki value shows 
stronger interaction. The scoring value of the interaction of vkh i. e-10.74 and-9.93 Kcal/mol and Ki 13.17ɳM and 53.04ɳM against the target 
protein EGFR and CA IX respectively while the reference drug cetuximab has shown binding energy-6.09 Kcal/mol with Ki value 34.44 µM and 
curcumin has shown binding energy-6.02 kcal/mol with Ki value 38.60 µM.  
Conclusion: It can be concluded that the molecule vkh could have potential to be used as an EGFR inhibitor and CA IX inhibitor. 
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Pyrimidines are the most vital heterocyclic aromatic organic 
compound containing two nitrogen atoms at positions 1 and 3 of the 
six-membered ring which shows the wide range of biological activities. 
These are the essential constituent of all cells and thus of all living 
matter. DNA and RNA is the main component of the chromosome 
carrying genetic information contain pyrimidine base in cytosine, 
uracil, and thymine. These occur in nature in two forms glycosylated 
pyrimidines and unglycosylated pyrimidines. Unglycosylated 
pyrimidines such as amino acids (ecotine), Vitamines (B1), antibiotics 
(Becimethrin, Bleomycin) and quinazoline alkaloids while 
glycosylated as DNA and RNA [1]. Pyrimidine derivatives have been 
reported as anti-neoplastic, anti-malarial, diuretic, cardiovascular 
agents [2]. Condensed pyrimidine derivatives have been reported as 
antimicrobial [3, 4], analgesic, anti-convulsants, anti-inflammatory [5], 
antibacterial, antitubercular [6], antifungal [7], and anti-tumor [8] 
agents. Anti-breast cancer activity of some novel pyrimidine 
derivatives has been also reported [9]. Various activities displayed by 
these nitrogen-containing heterocyclic rings such as pyrimidine made 
it, promising structural moiety for future drug design
Cancer is the most dreadful disease affecting the human 
population these days. It is characterized by abnormal growth of 
the cells. Different mechanisms account for the cytotoxic effect of 
pyrimidines, where they had been reported to act as glycogen 
synthase kinase (GSK) inhibitors [10], cyclin-dependent kinase 
(CDK) inhibitors [11], dual src/Ab1 kinase inhibitors, epidermal 
growth factor receptor (EGFR) inhibitors [12] and carbonic 
anhydrase (CA) [13]. In the present study, docking is performed 
against two macromolecules i.e. EGFR and CA IX. FDA approved 
EGFR as the successful target in colorectal cancer and various 
other types of cancers (as shown in table 1). The CA IX is reported 
to be associated with tumorigenesis being highly overexpressed in 
hypoxic tumors and restrictedly expressed in normal tissues. CA IX 
monoclonal antibody is already in Phase III clinical trials (as 
shown in table 1) and several small molecule inhibitors are in 
advanced preclinical evaluation with its overexpression in many 
cancer tissues and not in their normal counterparts [14]. This 
study includes the molecular docking study of the pyrimidine 
derivatives with EGFR and CA IX. All of the compounds were auto 
docked for the inhibition of the EGFR and CA IX. Cetuximab was 
taken as the reference drug in case of EGFR and curcumin for CA 
IX. This paper aims to elucidate the anti-cancer molecular 
mechanism of pyrimidines and provide the reference for its 
clinical application and further drug development. 
.  
  
Table 1: TTD ID of targeted receptor 
TTD ID  Target name  Target type Disease Drugs 
TTDS00355  Epidermal growth factor receptor Successful target Colorectal cancer, Cancers Cetuximab 
TTDR00211  Carbonic anhydrase IX Clinical trial target Cancer, Discovery agent Curcumin 
 
MATERIALS AND METHODS 
Procurement of sample 
The samples were procured from Saurashtra University and code name 
was given to each of the molecule vkb, vkc, vkd, vkf, vkg, and vkh 
respectively. The “IUPAC” name of samples was obtained by using 
ChemDraw online while the molecular properties were generated by 
using ACD chemsketch (freeware) 2015 2.5(as shown in table 2 and 3). 
Preparation of protein 
Three-dimensional structure of the protein should be retrieved from 
the RCSB Protein data bank (PDB); afterward the retrieved structure 
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should be pre-processed for removal of heteroatoms then energy 
minimization was performed by using Argus lab and visualization 
was done by using UCSF Chimera 1.11.2. Ramachandran plot was 
generated by using Discovery studio 3.5. 
 
Table 2: Chemical structure, code name and IUPAC name of compounds 

































Preparation of ligand 
Ligands can be retrieved from several databases such as ZINC, 
PubChem or can be sketched by applying the Chemsketch tool. Ligand 
2D structures were drawn using ACD chemsketch (freeware) 2015 2.5. 
Chem 3D viewer was used to convert the 2D structure into 3D. The 
drug molecules of cetuximab and curcumin were collected in 3D SDF 
format from the PubChem database. The compounds were added 
hydrogens and energy minimized with UFF force field using conjugate 
gradient algorithm by open babel in pyrx. All structures were saved as 
the pdb file format for input to pyrx 0.8. All the ligand structures were 
then saved in Pdbqt file format, for input into AutoDock version. Later, 
all lead molecules were converted into Auto Dock Pdbqt format. 
While picking out the ligand, the LIPINSKY'S RULE OF 5 should be 
utilized. Lipinski rule of 5 assists in discerning amongst non-drug 
like and drug-like candidates. It promises the high chance of success 
or failure due to drug-likeness for molecules abiding by with 2 or 
more than of the complying rules. For the choice of a ligand allowing 
to the LIPINSKY'S RULE: (1) Less than five hydrogen bond donors 
(2) Less than ten hydrogen bond acceptors (3) Molecular mass of 
less than 500 Da (4) High lipophilicity (not over 5) and (5) Molar 
refractivity should be between 40-130. The rule is important in the 
drug discovery process to ensure the selectivity of the compound or 
determine if a chemical compound has physical or chemical 
properties that would make it likely orally active. 
Docking 
Ligand was docked against the protein and the interactions were 
analyzed by using by pyrx 0.8. For the docking of ligands into 
protein active site and to estimate the binding affinities of docked 
compounds, an advanced molecular docking program AutoDock 
Vina (4) was used in this study. All computational studies were 
carried out using pyrx AutoDock wizard with MGL tools 1.5.6 
installed in a Pentium ®Dual–Core CPU T4200 machine running on 
a 2.0 GHz Intel core processor with 2GB RAM by using the 
lamarckian algorithm. The scoring function gives the score on the 
basis of best-docked ligand complex is picked out. 
RESULTS  
EGFR and CA IX is a clinically validated target for the treatment of 
various types of cancer and tumors has received considerable 
interest from the scientist in the design and development of newer 
anticancer drugs. The EGFR family plays an essential role in 
normal organ development by mediating morphogenesis and 
differentiation through effects on cell proliferation, differentiation, 
apoptosis, invasion, and angiogenesis [15, 16]. Whereas the CA 
from a family of enzymes that catalyze the interconversion 
between carbon dioxide and water and the dissociated 
 ions of carbonic acid (i.e. bicarbonate and protons) and leads to 
regulation of tumor microenvironment. This interconversion is 
a reversible reaction and the enzyme catalyzes both reactions, 
forward and reverse. The active site of most carbonic anhydrases 
contains a zinc ion; they are therefore classified as metalloenzymes 
[17]. This study is primarily concerned with the in silico molecular 
docking of six pyrimidine derivatives with EFGR and CA IX 
proposing their role as an inhibitor in cancer studies. These 
compounds are tested in silico for drug-likeness and anticancer 
activity by docking with the protein via pyrx docking software. 
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Table 3: Molecular properties of the compounds 















































































































































Nominal mass 444Da  462Da 429Da  423Da  400Da  484Da 










































































Table 4: Results of the lipinski rule calculator 
Compound Mass (Da) H bond donor H bond acceptors LOG P Molar refractivity 
Vkb 444 1 6 4.7463 124.68478 
Vkc 420 1 4 5.548411 117.3252 
Vkd 421 1 6 4.56482 114.10259 
Vkf 420 3 4 0.854811 115.55609 
Vkg 394 2 5 2.0183 110.24445 
Vkh 482 2 4 4.73961 138.71896 
 
Table 5: Output of molecular docking score of ligand-EGFR with respect to minimum binding energy and inhibition constant 
S. No. Name Run Minimum binding energy (Kcal/mol)  Inhibition constant 
1 vkb 6 -6.63 13.71 µM 
2 vkc 9 -8.03 1.29µM 
3 vkd 5 -7.77 2.03 µM 
4 vkf 8 -8.7 419.55 ɳM 
5 vkg 5 -7.7 2.26 uM 
6 vkh 5 -10.75 13.17ɳM 
7 Cetuximab 4 -6.09 34.44 µm 
 
The Protein-Ligand interaction plays a significant role in 
structural based designing. All the compounds have shown ≥5 
hydrogen bond donors, ≥10hydrogen bond acceptors, molecular 
mass ≥500 Da, highly lipophilic in nature and molar refractivity 
between 40-130 (except for vkh has shown molar refractivity of 
138.71) as shown in table 4. The rule describes molecular 
properties imperative for drug's pharmacokinetics in the human 
body, including their absorption, distribution, metabolism, and 
excretion.  
Docking studies of pyrimidine derivatives with both the receptors 
revealed that all the compounds have lower binding energy and 
inhibition constant (Ki) value than reference drugs. 3-D structure of 
EGFR, Ramachandran plot of EGFR and various docked conformations 
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and active site interactions with EGFR have been shown in fig. 1 and 3-D 
structure of CA IX, Ramachandran plot of CA IX and various docked 
conformations and active site interactions with CA IX have been shown 
in fig. 2. Further details of important interactions in terms of energies 
between ligands and the proteins with EGFR and CA IX receptor with 
predicted Ki values are shown in the table is given in table 5 and 6. 
 
Table 6: Output of molecular docking score of ligand-CA IX with respect to minimum binding energy and inhibition constant 
S. no Name Run Minimum binding energy (Kcal/mol) Inhibition constant 
1 vkb 7 -7.83 1.82 µM 
2 vkc 9 -9.47 114.57 ɳM 
3 vkd 9 -7.17 5.55 µM 
4 vkf 5 -8.4 690.47ɳM 
5 vkg 5 -9.39 131.71 ɳM 
6 vkh 9 -9.93 53.04 ɳM 
7 Curcumin 4 -6.02 38.60 µM 
 
 
Fig. 1: (a) 3D structure of EGFR; (b) Ramachandran plot of EGFR; (c) Docking of EGFR Protein receptor with Cetuximab; (d) Docking of 
EGFR Protein receptor with vkb; (e) Docking of EGFR Protein receptor with vkc; (f) Docking of EGFR Protein receptor with vkd; (g) 
Docking of EGFR Protein receptor with vkf; (h) Docking of EGFR Protein receptor with vkg; (i) Docking of EGFR Protein receptor with vkh 
 
Sharma et al. 




The EGF is the prototype of a large family of peptide ligands that 
bind to cell membrane receptors and activate a myriad of 
intracellular signaling pathways to control tumor cell growth, 
proliferation, survival, metastasis, and angiogenesis [18]. Whereas 
CA IX enzymes catalyze a very simple physiological reaction, the 
interconversion between carbon dioxide and the bicarbonate ion, 
and are thus involved in crucial physiological processes connected 
with respiration and transport of CO2/bicarbonate, pH and CO2 
 
homeostasis, electrolyte secretion in a variety of tissue/organs, 
biosynthetic reactions, bone resorption, calcification, tumorigenicity 
and many other physiologic or pathologic processes [19]. In this 
work, totally 6 compounds which are pyrimidine derivatives were 
examined for ligand-based docking. The ligands are screened for 
their ability to dock within the active site of the inhibitor protein. All 
the compounds have shown ≥5 hydrogen bond donors, 
≥10hydrogen bond acceptors, molecular mass ≥500 Da, log P value 
≥5 and molar refractivity between 40-130 (except for vkh has 
shown molar refractivity of 138.71) which means compounds have 
good oral bioavailability. The Ramachandran plot generated displays 
the dihedral angles φ and ψ for each residue in the protein that is 
displayed in the workspace. The plot area displays a plot of protein 
dihedrals for all residues in the protein. The area "green region" 
corresponds to "core" region representing the most favorable 
combinations. Ideally, 90% of the residues should be in this “core” 
region. After analyzing the different docking interactions of ligands, 
out of the 6 inhibitors analyzed vkh has shown the binding energy 
of-10.74 and-9.93 Kcal/mol and Ki 13.17ɳM and 53.04ɳM against 
the target protein EGFR and CA IX respectively. The best drug was 
selected, depending upon the binding energy and Ki. Smaller Ki 
value shows the stronger interaction [20, 21]. Out of the 6 
derivatives compound, vkh shows the highest affinity towards the 
protein compared with the standard drug cetuximab and curcumin. 
Thus compound vkh may act as a better and efficient anticancer 
drug.
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Fig. 2: (a) 3D structure of CA IX; (b) Ramachandran plot of CA IX; (c) Docking of CA IX Protein receptor with Cetuximab; (d) Docking of CA 
IX Protein receptor with vkb; (e) Docking of CA IX Protein receptor with vkc; (f) Docking of CA IX Protein receptor with vkd; (g) Docking of 
CA IX Protein receptor with vkf; (h) Docking of CA IX Protein receptor with vkg; (i) Docking of CA IX Protein receptor with vkh 
 
CONCLUSION 
EGFR kinase domain and CA IX have been emphasized in the majority of 
cancers including colorectal cancer, breast, lung, ovarian, anal cancers, 
and tumors etc. Owing to their dominant role in cancer, molecular 
docking of EGFR and CA IX against the pyrimidine molecule was carried 
out. Based upon the results obtained from the docking study in the 
present study all the compounds may be suggested as the potential 
therapeutic drug for the treatment of cancer. However, vkh has a strong 
interaction and binding with target protein as evident by docking score. 
Further in vitro and in vivo experimental work is required for validation 
of our in silico results and to generate more effective and potential drug 
through ligand-based drug designing approaches. 
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